The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer

Table 1

Patients’ characteristics.

		Number (%) or median (mean ± SD)			value
		Total	NLR < 2.59	NLR ≥ 2.59
Number of pts.		73	34	39
Age		72 (70.3 ± 6.7)	72 (69.8 ± 6.4)	71 (70.8 ± 6.8)	0.444
Gleason score	6	2 (2.7%)	0 (0.0%)	2 (5.1%)	0.664
	7	7 (9.6%)	3 (8.8%)	4 (10.3%)
	8	22 (30.1%)	12 (35.3%)	10 (25.6%)
	9	27 (37.0%)	12 (35.3%)	15 (38.5%)
	10	12 (17.8%)	6 (17.6%)	7 (17.9%)
	Unknown	2 (2.7%)	1 (2.9%)	1 (2.6%)
T stage	2	4 (5.5%)	4 (11.8%)	0 (0.0%)	0.096
	3	48 (65.8%)	21 (61.8%)	27 (69.2%)
	4	12 (16.4%)	6 (17.6%)	6 (15.4%)
	Unknown	9 (12.3%)	3 (8.8%)	6 (15.4%)
Lymph node metastasis		57 (78.1%)	26 (76.5%)	31 (79.5%)	0.978
Bone metastasis		36 (49.3%)	15 (44.1%)	21 (53.8%)	0.552
Lung metastasis		8 (11.0%)	4 (11.8%)	4 (10.3%)	0.865
Liver metastasis		6 (8.2%)	3 (8.8%)	3 (7.7%)	0.801
Pre-DOC PSA		52.7 (315.1 ± 782.7)	30.1 (196.7 ± 529.9)	57.4 (412.8 ± 930.3)	0.196
PS	0	50 (68.5%)	23 (67.6%)	27 (69.2%)	0.734
	1	9 (12.3%)	3 (8.8%)	6 (15.4%)
	Unknown	14 (19.2%)	8 (23.5%)	6 (15.4%)
No. of DOC		8.0 (9.7 ± 7.8)	10 (10.6 ± 7.9)	7.0 (8.9 ± 7.7)	0.412
Hb		12.1 (11.8 ± 1.6)	12.3 (12.1 ± 1.3)	11.5 (11.4 ± 1.7)	0.036
ALP		726 (955.5 ± 903.2)	236 (596.0 ± 637.6)	841 (1135.2 ± 960.9)	0.160
LDH		217 (269.8 ± 167.4)	199 (250.4 ± 183.2)	233 (284.4 ± 148.6)	0.432